Company description
Dr. Justin Kaner graduated with a B.S. in Biology from Syracuse University in 2009 where his initial interest in hematologic malignancies developed. He received his M.D. from New York Medical College in 2013 before completing his Internal Medicine Residency at Albert Einstein College of Medicine/Montefiore Medical Center. During residency Dr. Kaner pursued his interest in hematologic malignancies by undertaking several research projects mainly focused on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) which led to several publications in peer reviewed journals, including Leukemia and Lymphoma and Oncotarget, as well as numerous abstracts presented at the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) Annual Meetings. Additionally, Dr. Kaner served as Chief Resident after his residency at Montefiore Medical Center.Throughout his Hematology/Oncology fellowship at Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Kaner worked in the laboratory of Dr. Monica Guzman and with clinical mentorship from Dr. Ellen Ritchie and Dr. Gail Roboz of the Weill Cornell Leukemia Program. During this time, he studied the activity of a novel therapeutic, PU-H71, in PTPN11 mutated AML as well as the prognostic impact of PTPN11 mutations in AML. During his fellowship training Dr. Kaner also developed a particular interest in early phase clinical trials and novel therapeutics for the treatment of Relapsed/Refractory AML. Dr. Kaner accepted an opportunity to remain at Weill Cornell, joining the Leukemia Program to focus on caring for hospitalized patients with various acute and chronic leukemias, MDS and myeloproliferative neoplasms (MPNs).
